text:
How the Fed got from eternity to here – FT.com
October 30, 2014 By dralfoldman in Business Administration, Central banks, Euro Crisis, Fiscal Policy, Monetary Policy, Politics	1 Comment
English: The Marriner S. Eccles Federal Reserve Board Building (commonly known as the Eccles Building or Federal Reserve Building) located at 20th Street & Constitution Avenue, NW in the Foggy Bottom neighborhood of Washington, D.C. Designed by architect Paul Philippe Cret in 1935, construction of the Art Deco building was completed in 1937. Its 2009 property value is $109,029,200. (Photo credit: Wikipedia)
This is currently the Financial Times' most-read article. It's a recommended read. Check it out!
How the Fed got from eternity to here – FT.com.
The article looks at the history of QE. QE hass been incredibly succesful but it has had negative consequences, especially in the developing world. The Eurozone failed to embrace QE effectively because of political push-back from Germany.
I wonder how history will judge QE?
« QE central bankers deserve a medal for saving society – Ambrose Evans-Pritchard Telegraph
Opinion – Boehner: Bush would have punched Putin in the nose – CNN.com »
john a gelmini says:
Like Dr Alf I wonder.
QE which basically means the electronic equivelent of printing more money can have good short term effects but in the long run it means that the value of the currency being "quantitatively eased" will fall.
For a short time people in the City and bourses around the world can make a killing and lower down the food chain exporters find it easier to export and jobs can be created by producing and shipping those goods.
Countries with competitive underlying economies and companies run by people interested in exporting therefore do well out of QE but countries like the UK which once had a fine exporting mindset and is now populated by risk averse directors interested in lining their own pockets and taking few risks gains little from QE as the benefits get squandered on creating housing bubbles which are flash in the pan.
We now hear that after $3.7 trillion USD,s worth of QE the process has been stopped in America because to have continued would render the US dollar about as valueable as the Zimbabwean currency and the images that Germans are brought up to fear of wheelbarrow loads of cash being taken to the shops to buy little more than a day's food.
With Europe QE could still be a remedy of a time limited nature but in its absence there has to be a concerted ,messianic effort to export things and get the less academically inclined to go into business for themselves and start new lives abroad in places like Brazil which have the space and populations of similar heritage.
The Chinese are already doing this with their "Go Out and Bring Back In " policy whereby their non academically qualified people are encouraged to go abroad,set up businesses,stay abroad and send money back home to support elderly relatives left behind.
Europe needs to follow that example whereby young Portuguese and Spanish people who would otherwise be unemployed in their own countries should go to Brazil,Argentina and Uruguay plus perhaps Chile,young Italians might be sent to Argentina.
Young unemployed Britons are in their present form,largely unexportable because they lack language skills and the motivation to thrive in a new ,alien and challenging environment.
Like the horses owned by landowners during the First World War they must be "brought into condition" prior to being sent overseas.
Then,after that they must be encouraged to leave through modern arrangements modelled on the old "Assisted Passage Scheme" Harold MacMillan and the Australian Government dreamt up as a solution to too many people in the UK during the 1950's.


text:
What is the difference between history and the past? Whose stories are told and whose are forgotten or ignored? Who gets to decide which histories are shared? How does where we live affect how we live? Students who participate in our school programs tackle these and other big picture questions to understand their own role in the history of our city, state and country.
HistoryMiami Museum's school programs are led by trained Museum Educators and designed to provide age and grade-level appropriate experiences, while focusing on different learning modalities. Critical thinking is elicited as students compare and contrast the past and present and are encouraged to visualize and question what the future should be.
All programs correlate to state educational standards. Programs also address curriculum areas beyond social studies, including language arts, mathematics and science where possible
For more information, please contact our registrar Olgasabrina Rueda at orueda@historymiami.org or click here for bookings.
In-person Programs for Schools, Camps and Clubs
In the interest of safety for our visitors and staff, and following official guidance, in-person programs for schools, camps and clubs are not available at this time.
A Day @ the Museum Immerse your class in a meaningful, hands-on, guided museum experience as you explore our collection and galleries.
Museum on the Go! Let us come to you! Students will explore the history of our community, our region, and our world through interactive hands-on experiences. Build the connection between the past, present and future with these dynamic and portable programs.
'round Town Explore your community and immerse yourself in the past. Enjoy the sights and sounds of our local history at one of our local historic sites.
Virtual Programs for Schools, Camps and Clubs
Select the Self-guided virtual tour of the Tropical Dreams exhibition and you will find text you can assign as readings, links to videos and other resources for further research and ideas for activities that you can modify and make your own.
Or, view our selection of Guided Virtual Programs and then book a guided virtual program hosted on Zoom for a different experience.
Looking for resources just for teachers? Try these!
Virtual programs are made possible thanks to the support of Amerant Bank.
F.A.Q. and School and Camp Policies Click Here.

redpajama_set_name: RedPajamaCommonCrawl


Today Apple finally introduced it's long waited iPhone. iPhone combines three products – a mobile phone, a widescreen iPod with touch controls, and an internet communications device with email, web browsing, maps, and searching. iPhone also introduces an entirely new user interface based on a large multi-touch display and pioneering new software, letting you control everything with just your fingers.
You can watch the whole iPhone introduction from HERE.
I just watched it and it was really cool device but I couldn't stop thinking do you really need your both hands to use it. I've so used to use my mobile phone with just one hand and do something else with the other. Go figure.
Looks good but I'd have to believe the crowd for whom it would be a must-have would be mighty small. Of course, there are those who can afford toys like these whether they need them or not.
nice phone.looks like apple is conquering the technology.


Now that the eurovox is dead and well buried is it time to close it altogether. I think so, if you look theres only been a handful of posts in the last few months and most are just speculation. It seems as if eurovox is cluttering up the forum.
Satsmo it just annoys me seeing it there at the left hand side of the home page when we all know theres no point in it anymore.
As said will take a look at it and see what we will do. I understand it is dead in regards to the UK and the majority of the rest of the globe.


The Iron Guppy, a new custom 20 metre (65') ice breaking tug designed by Robert Allan Ltd of Vancouver is taking shape at Hike Metal Products Ltd in Wheatley, Ontario.
The tug is under construction for Ports Toronto and will replace the 1961 vintage William Rest which has served the port well for many years. Iron Guppy was named by Waterfront Elementary School students from a longlist of names developed by students from kindergarten up to Grade 6.
The new tug carries over some of the old tug's characteristics such as size, power, and single fixed pitch propeller that the crew have become accustomed to. With a special ice breaking bow it will be able to break at least 6 inches of ice continuously and up to 10" ramming.It will be powered by a single 750 hp Cummins QSK19-M engine turning a 53" five-bladed propeller.Bollard pull will be 6 tons.It is arranged for a crew of up to 6 persons and is fitted out as a "day boat" with a large crew lounge and pantry but no overnight accommodations.The wheelhouse will have excellent visibility all around including to the quick release towing hook on the aft deck. Delivery is expected sometime in June, 2016.


In 2012, my husband and I were caught up in a bit of a tussle with our local municipality, when we found out the hard way that the four backyard chickens we had were against the local bylaw. When they told us we needed to find them a new home – pronto – we immediately set out to change this silly Bylaw and a year later, in February 2013, we met with success! Council officially adopted a new bylaw, allowing residents to keep backyard chickens on less than an acre of property. To our surprise the new bylaw also included a section about urban beekeeping. We were excited and relieved that we could keep our chickens, but what's this about bees…..honeybees? Interesting.
Since that time, we have taken courses, joined a local club, worked with a mentor who is AMAZING and our apiary has grown to 7 hives – we are up to our ears in bees and loving it! My Husband now makes and sells hive boxes, frames, solar wax melters, inner covers, outer covers, bottom boards, full nuc boxes…. you name it, he makes it.
We also have learned the importance of mite management along the way. We sell oxalic acid vaporizers which have quickly become one of our more popular products, and can be ordered online.


Four years of religious Shellac use later and my nails resemble those thin blotting papers you use to de-shine your T-zone. They're short, brittle and they break at the drop of a hat. Not ideal. Crappy nails aside, we recently wrote about how the UV nail lamps can increase your skin cancer risk. For these two reasons, I've decided to break up with Shellac and start using a new polish method called SNS.
SNS is basically what you'd get if Shellac and acrylics had a super-baby. It stands for Signature Nail Systems and it's gained a lot of popularity over the last few years. It's almost the same price as Shellac, doesn't ruin your nails and doesn't require setting with a UV lamp.
"SNS is a nail dipping system that uses a brush-on gel base on the nail, which is then dipped in a powder. The powder comes in natural pink and white for a french manicure look, as well as a range of colours." — Nail educator, technician and blogger Julie Morrow via Mamamia.
One of the reasons Shellac can ruin your nails is because it's not very flexible. Because of this, it can cause the nail to bend inwards which can lead to breakage. Not only does this not happen with SNS, the dipping powder also helps to grow and strengthen your nails! Yep, this is one of the rare occasions where something actually isn't too good to be true.
But it's always better to fix the root of a problem, rather than just slapping a (metaphorical) band-aid over it. So even if you are keen to make the switch from gel to SNS, here are some other things you can do to help make your nails long and strong again.
Adding a natural supplement to your daily routine can go a long way in promoting quick nail growth. The added bonus is that they also happen to be fantastic for your hair and skin! We love this one from Vida Glow because it comes in five different flavours and you can add it to your smoothies.
Don't worry, we're not going to suggest you stop showering! But just make sure to wear gloves when you're washing the dishes, as the combination of water and harsh chemicals can damage your nails.
Brushing some cuticle oil onto your nails each day will help increase circulation and stimulate new nail growth. Make sure you go for one that includes vitamin E, as this is the miracle ingredient for nourishing your nails. We love the SolarOil Nail and Cuticle Conditioner from CND Essentials.
The absolute worst thing you can do to your nails is rip the gel polish off yourself. This is actually half the reason many people have such brittle nails after using Shellac! If you are going to keep using gel or SNS polish, ensure you always always have it properly removed by a nail technician.
As mentioned, avoiding abrasive chemicals is important when strengthening your nails. But there are plenty of natural ingredients you can soak your hands in to speed up nail growth! Olive oil, coconut oil, lemon and oranges all work wonders.


text:
Smarter People Have More Sex, Do More Drugs And Stay Up Later Because It's The Smarter Thing To Do
A new study has found that smarter people not only tend to stay up later, but also regularly engage in recreational sex and drug use.
According to Esquire magazine, English researchers recently discovered that students at prestigious schools like Oxford and Cambridge spend much more time having sex, smoking weed and staying up later than their peers at less reputable institutions.
The research was funded by sex toy retailer Lovehoney.co.uk, where Oxford and Cambridge students have spent a combined $31,461.
"The correlation probably has something to do with the open-mindedness that comes with intelligence," 23-year-old Annalisa Rose, an employee of high-end sex shop "Honey" in Williamsburg, Brooklyn, told Esquire. "I think that the ability to engage in an open sex life comes with the abilities of introspection and logical thought, and those require some level of intelligence. If we're talking about an open sex life that comes from an emotionally healthy place, sexual mores are mostly made up anyway and intelligent people can rationalize past them," she said.
Many previous studies have found that people with higher IQs, better jobs, or degrees from top-notch universities are more likely to smoke weed or even snort a few lines here and there.
Esquire reports that this is because these people tend to pursue insightful experiences involving adventure and mental expansion.
Smart people will indulge in most opportunities that could potentially broaden their minds.
They also more closely understand addiction and moderation and are therefore less fearful of engaging in drug use.
A 2010 study seen in Psychology Today showed that those with an IQ of 125 or higher are exponentially more likely to use drugs.
From the study:
"Net of sex, religion, religiosity, marital status, number of children, education, earnings, depression, satisfaction with life, social class at birth, mother's education, and father's education, British children who are more intelligent before the age of 16 are more likely to consume psychoactive drugs at age 42 than less intelligent children. "... there is a clear monotonic association between childhood general intelligence and adult consumption of psychoactive drugs. 'Very bright' individuals (with IQs above 125) are roughly three-tenths of a standard deviation more likely to consume psychoactive drugs than 'very dull' individuals (with IQs below 75)."
The final element of our genius-trifecta is proven valid in an academic paper entitled "Why the Night Owl is More Intelligent," published in the journal Psychology and Individual Differences.
The paper, Esquire reports, highlights that for several millennia, humans have been conditioned to work during the day and sleep at night.
Those that break this cycle, the paper says, "may be more likely to acquire and espouse evolutionarily novel values and preferences than less intelligent individuals."
The paper goes on to say that liberals who don't believe in God are more likely to be intelligent as well.
It seems that the gist here is that progressive thinkers who uphold adventure and experimentation over safety and tradition are the more intelligent beings.
So as Esquire says, "if you're getting laid at 3 am on Sunday morning and have a full bowl packed beside the bed and you aren't going to church the next day, you're probably a genius."
There you have it. Not only are those who rebel against conservatism sexier and much more fun to hang out with, but contrary to popular belief, they're also smarter and more groomed for success.
Oh, and we work our assess off too, so don't even think you've got that one on us.
Via: Esquire, Top Photo Courtesy: Wolf Of Wall St


The purpose of this Directive is to delegate, clarify and specifically confirm certain authorities of the Secretary of the Department of Health and Human Services to the Director of the Division of Information Resource Management. This position shall report to the Secretary through the Deputy Secretary for the Department.
The purpose of this directive is to delegate, clarify and specifically confirm certain authorities of the secretary of the North Carolina Department of Health and Human Services (NC DHHS) to the director of the Division of Information Resource Management (DIRM). The director of DIRM shall serve as the Chief Information Officer for DHHS. This position shall report to the secretary through the Deputy Secretary for the department.
The DIRM supports the business functions of the DHHS by providing the department and its divisions and offices with both information resource management (IRM) policy and planning services, and information technology (IT) services. Both information resource management and information technology services shall be in partnership with the DHHS divisions/offices.
DIRM shall continuously strive to enhance the department's maximization of enterprise IT solutions and efficiencies. These enterprise solutions further develop and implement IT consolidation by coordinating efforts, avoiding duplications and producing accountability for the IT resources.
IRM policy and planning services shall include, but not be limited to, assistance in: (1) policy research, analysis, and development; (2) policy compliance monitoring; (3) short term and long term planning; (4) quality assurance; (5) system-wide security and privacy protection against both deliberate and accidental intrusions and disasters; (6) IT business continuity and disaster recovery planning and implementation; (7) IT project management; (8) compliance with S.L. 2004-129 (Senate Bill 991) requirements; (9) IT procurement and (10) HIPAA coordination..
IT services shall include, but not be limited to, assistance in: (1) computer application systems software planning, development, transfer, maintenance and modification; (2) telecommunications and network design and management support; (3) computer hardware planning and installation support; (4) technical assistance and consultation in all areas related to the acquisition and installation of computer hardware and software and (5) IT security.
The DIRM shall work with departmental and divisional management to help ensure the availability and integrity of high quality automated information systems for the department and its constituent divisions and offices. The DIRM shall provide continuous review of all IT projects proposed and/or initiated throughout the department and departmental divisions, shall maintain a complete inventory of all such technology projects including ongoing project status, and shall assist in the coordination of those projects having planned or potential department-wide or multi-divisional applications. As the DHHS Chief Information Officer (CIO), the director of DIRM shall have the authority and responsibility for approving all projects that meet S.L. 2004-129 (Senate Bill 991) requirements. The DIRM shall serve as the primary liaison to the State CIO's Office, more specifically the State's Enterprise Project Management Office (EPMO) in relation to projects subject to S.L. 2004-129 (Senate Bill 991).
The DIRM shall oversee and coordinate the establishment and on going operations of a privacy and security program for the department's information resources, including policies, procedures, standards to protect the availability and integrity of hardware, software, telecommunication network, applications and IT business continuity .
The purpose of this directive is to enable the DIRM to fulfill its function to consult, coordinate and advise the department and its divisions through the delegation of certain authority by the Secretary of the DHHS to the director of the DIRM.
The functions of management, related to the DIRM, as defined in G.S. 143B-10, which include: planning, organizing, staffing, directing, coordinating, evaluating, reporting and budgeting.
Shall research and provide the ongoing review, of all existing federal, state, and departmental IRM and IT policies, procedures and standards. Such research and review shall be conducted for the purpose of making recommendations to the secretary, the deputy secretary, the assistant secretaries or the senior advisor, for the revision of existing departmental information technology policies, and/or the development and adoption of new policies, in areas related to the role of automation, the scope of automation, the objectives of automation, and/or the acquisition, allocation, management, and security of automation resources. The director of DIRM shall review any policy modifications proposed by departmental division management and make recommendations to the secretary, the deputy secretary, the assistant secretaries or the senior advisor, with respect to such proposals.
Shall verify compliance with all federal, state, and departmental IRM policies. The director of DIRM shall monitor the implementation of all federal, state and departmental IRM policies by the department and its divisions and offices. Appropriate departmental or divisional management shall be notified of any failure to comply with established policies, and the director shall work with management to implement corrective action. Should such corrective action not be established, the director shall notify the secretary, the deputy secretary, the appropriate assistant secretary or the senior advisor.
In coordination with the secretary, the deputy secretary, the appropriate assistant secretary or the senior advisor the director of DIRM shall serve as the department's principle advocate and liaison on matters of IRM policy with federal, state and local agencies. The director shall serve as a principle advisor to the department's executive management team on all IRM issues, and provide appropriate consultation and guidance to all divisions and offices within the department to ensure compliance with established policies.
The director of DIRM shall assist in and coordinate the development of short and long range strategic IRM and IT plans for the department and departmental divisions. These plans shall meet the requirements established by applicable legislation, the Office of the State CIO and the Office of Information Technology Services (ITS). In coordination and consultation with the secretary, the deputy secretary, the appropriate assistant secretary or the senior advisor the director may establish additional requirements for such IRM and IT plans, and shall monitor the implementation of such plans. The requirements for IRM plans shall address the management of the department's and departmental divisions' data as an organizational resource and provide for (1) compatible databases; (2) consistent field definitions to the maximum extent possible; (3) coordinated usage of common data throughout the department; (4) adherence to statewide and DHHS architecture standards; (5) adoption of statewide and DHHS security requirements and (5) maintenance and on-going IT operations. The requirements shall include the determination of both anticipated development and maintenance costs related to proposed projects, and anticipated funding sources.
Shall review, approve, or deny all federal Planning Advance Planning Documents (PAPD's), Implementation Advance Planning Documents (including APD updates), all requests for proposals (RFP's) and other IT procurement documents for systems originated by the department or any departmental divisions or offices. The DIRM review shall be performed in coordination and consultation with the department's Office of the Controller, the Office of Procurement and Contracting Services and the Division of Budget and Analysis. After proper review and consultation, the director shall make recommendations to the secretary, the deputy secretary, the appropriate assistant secretary or the senior advisor regarding approval. DIRM shall then monitor the implementation of all such approved documents to verify compliance with all document provisions and established requirements.
Shall provide technical consultation and guidance to all departmental divisions and offices on IRM planning and IRM policy development. DIRM shall provide assistance and coordination in the development of concepts, goals and objectives of all computer systems, on automation resource acquisition and management, on grant proposals for automation services, and on training for automation planning and management issues.
Shall research existing federal, state and departmental IRM policies and propose modifications or additions to those policies in order to establish necessary requirements for, coordinate the development of, and monitor the implementation of the department's data and information resource security and disaster recovery programs by the department and its divisions and offices.
Shall review, approve or deny all requests for automation projects that involve the acquisition of custom developed software, and the customization of off-the-shelf software that include federal financial participation made by local governmental agencies such as county DSS offices, public health departments or local management entities. This review shall ensure that, per federal requirements, all human service automation projects are statewide in scope and operation. DIRM shall work with the respective DHHS divisions or offices and representatives of the affected local agencies to establish the process for the review and approval of requests.
Shall review and approve the acquisition of all information technology resources (e.g., computer hardware, software, consulting services, etc.) proposed by all departmental divisions and offices, regardless of funding source. The review shall include, but not be limited to, a determination of whether or not the IRM resources proposed to be acquired meet the requirements that have been specified by the purchasing division or agency. The director's approval or disapproval shall be consistent with applicable federal, state, or departmental policies, standards, and guidelines. The director shall promptly communicate any concerns, problems, or difficulties DIRM may determine in its review to the appropriate departmental division director in an effort to seek possible solution. Should a solution not be established, the director shall notify the secretary, the appropriate assistant secretary, or the senior advisor.
Shall monitor and ensure that departmental system designs and applications are consistent with the ITS, the Office of the State CIO and DHHS IT policies, procedures, standards and requirements. DIRM shall ensure that project management methodology and consistent technical standards are developed, maintained, and followed in the design and implementation phases. DIRM shall use the S.L. 2004-129 (Senate Bill 991) reporting requirements and the DHHS IT policies and procedures in approving or denying IT projects and operations. This review process must also take into consideration the maintenance and ongoing operational costs of the system or change.
Shall serve as the department's principle liaison with ITS. DHHS divisions/offices shall be involved in the communication with ITS to ensure that the business needs of the respective divisions are represented. As the principle liaison, DIRM shall establish mechanisms to gather from and distribute to DHHS divisions and offices information to achieve effective and efficient departmental IT operations and support.
In partnership with DHHS divisions and offices, DIRM shall provide consultation, technical assistance and oversight for HIPAA (Health Insurance Portability and Accountability Act) implementation and oversight. DIRM shall designate a DHHS Privacy Officer and DHHS Security Officer.
Shall consult with and keep the secretary, the deputy secretary, the appropriate assistant secretary or the senior advisor informed on all priority issues related to the impact of new technology, the delivery of automation services, and the operation of automated systems within the department. DIRM shall serve as a principal voting member on the DHHS Information Technology Governance Committee (ITGC) and shall provide staff support to the ITGC.
Shall implement a process to receive, review and approve/deny waivers to adherence to DHHS IT policies, procedures, standards and requirements. The process shall be a DHHS policy.
Shall provide a clearinghouse for used departmental hardware and software assets to determine if the assets have any departmental use before surplusing. DIRM shall develop procedures for the DHHS divisions and offices to follow when surplusing or disposing of hardware or software to ensure DIRM's inspection of potential surplused assets.
Shall be responsible for the development, coordination and maintenance of an automated or physical inventory of all DHHS IT assets. This inventory is intended to supplement and not replace the DHHS Controller's Office Fixed Asset responsibilities. DHHS divisions and offices shall provide assistance and cooperation to DIRM as requested to develop and maintain this IT inventory.
This delegation of authority shall not deprive the secretary from performing, in lieu of the director of the DIRM, any of the acts set forth above. This delegation of authority may be amended or withdrawn by the secretary at any time and without notice. This delegation of authority shall not apply to any action, which by law, state policy, or NC Governor's Executive Order, may only be executed by the secretary.


text:
Home » Trump Rants in Near-Empty White House: I'll 'Never' Say Biden Won
Trump Rants in Near-Empty White House: I'll 'Never' Say Biden Won
Thursday, January 14, 2021 at 3:45 AM
Credit: Photo Illustration by Kelly Caminero/Getty
Late afternoon on Wednesday, President Donald Trump made history, yet again. For his role in instigating last Wednesday's bloody pro-Trump riot at the U.S. Capitol, the House of Representatives voted to impeach this president for the second time in roughly a year, making Trump the only president in American history to get impeached twice.
But for all the historic weight of the day, the Trump White House remained mostly quiet, drained of energy and much of its personnel. The president drifted in and out of the Oval Office, monitored the impeachment process on TV, and found time to award a medal to country singer Toby Keith. But by the time the sun fell on Washington, the president had yet to make a public appearance or emerge to pelt insults at the reporters on the premises. He couldn't rage tweet about the latest impeachment or the Republicans on Capitol Hill who had gone along with it, because Twitter had already taken his Twitter away. And his staff was a husk compared to what it was just over a week ago, following a series of high-profile resignations from the administration last week and a steep plummet in morale in the building since the riot and death toll. Some West Wing brass, including White House Chief of Staff Mark Meadows, have spent recent days purposefully keeping a distance from Trump, as various advisers live out the final moments of the era by attempting to avoid triggering the president's temper or making matters worse, somehow.
While photographers, reporters, and staff gathered at the White House, the president was sealed off by his aides, kept out of sight from the press. Even for Trump's feel-good, arts medal ceremony held in the East Room, the cameras were barred. A U.S. Marine who kept appearing, then disappearing, at the entrance to the West Wing multiple times. It was practically the only indicator of whereabouts. (The Marine typically stands guard at those doors when the president is in the Oval Office.)
Read more at The Daily Beast.
Got a tip? Send it to The Daily Beast here
Karl Rove: 'Strong Likelihood' Trump Will Be Convicted if Giuliani Leads Impeachment Defense
'Destroy Trump': Breitbart Staffers Seethe After Capitol Riot
MyPillow Guy Presents Trump With 'China' Election-Fraud Theory, Lawyers Send Him Packing
Capitol Rioter Threatened to Shoot His Kids If They Snitched: Feds
AOC proposes funding to deprogram white supremacists
previousAmazon Reveals The TERRIFYING Reason They Suspended Pro-Trump Social Network Parler!
nextAUS vs IND 4th Test: Can team India breach Fort Gabba, the fortress where home team are undefeated over 32 years


It's the right time to create your own brand with us!
Come with us on a journey of making your business online. Since 2008, we are in the business of catering our customers with marketing strategies. Whether it is related to web application development and designing; we work towards the enhancement of visitors to your website. Grow your business by attracting the maximum benefits. Precision, professionalism, and perfection are what our team follows to approach the expectations of our clients.
Paying attention to your brand identity.
Look out for key objectives.
Assuring the consistency of your business performance.
Tracking the success of your project.
Our responsive designs allow your clients to access the website whenever they want. The users can easily navigate to different pages.
Get the chance to access the highly optimized and SEO friendly websites without any trouble. Enjoy fast loading and achieves the higher rankings.
Increase your online sales by getting excellent support from our team. We're not only your website development company, we're the partners of your business.
Your customers will love you if your website design is totally mobile friendly. This intelligent strategy increase helps in enhancing the customer's traffic and holds your business in your hand.
Customize your business with the unique designs we offer to our clients. Every design has its inimitable look and feels that define your business very well.


text:
Home > Travel
Delphi: Greece's underground classic
13 Jul, 2019 12:10pm 8 minutes to read
Glorious unknowns and unpredictable adventures: Philippines on a budget
Everything about Space Tourism you were too afraid to ask
In space no one can hear you dream: Stanley Kubrick's 1968 film expected us to be in space by now. Photo / George Rinhart, Getty Images
By: Hannah Sampson
Space suddenly seems a little more reachable - at least, for those who have cash to burn.
Virgin Galactic's announcement Tuesday that it is going public through a merger with an investment firm came with an update that the company is preparing to send its first customers into space within a year, CNBC reported. More than 600 people have placed deposits topping $80 (NZ$120) million in total, chairman Chamath Palihapitiya told the network, and another 2,500 want to get in line.
Blue Horizon: Washington Post owner, Jeff Bezos's pet project is getting punters into space. Photo / Getty Images
Virgin isn't alone in the space race: Blue Origin, Jeff Bezos' space exploration company, is promoting "the largest windows in space" on its New Shepard capsule, although test flights with humans onboard have not yet taken place. (Bezos owns The Washington Post.) Elon Musk announced last year that his company, SpaceX, has a customer lined up who will pay to fly around the moon. Last month, NASA made a change in policy and said it would allow space tourists to visit the International Space Station as soon as next year. The agency said logistics would have to be arranged by SpaceX and Boeing, which NASA has tapped to get crews to the space station.
So will we all be jetting around space with our cameras, orbital passports and zero-gravity fanny packs in a decade? Not so fast. Here's what potential space explorers need to know.
What does space tourism involve?
The most widely touted versions involve rocketing passengers more than 50 miles into the atmosphere and achieving minutes of weightlessness and witnessing Earth views before returning to land. Virgin Galactic and Blue Origin differ in the details of how they will get to space and the altitude they'll reach, but they are promoting relatively similar experiences and plan to carry six passengers at once.
To infinity . . . An Astrium Space Jet mock up at the Paris Airshow. Photo / Getty Images
There are even more ambitious offerings: Space Adventures, which has sent seven people to space as tourists, offers multiday experiences including a "circumlunar" mission, a trip to the International Space Station and a spacewalk add-on; the company has contracted with Boeing to help sell seats aboard its spacecraft. Bigelow Space Operations, a branch of space-technology company Bigelow Aerospace, said last month it had "paid substantial sums as deposits and reservation fees to secure up to four SpaceX launches to the International Space Station."
For those craving weightlessness without the actual space travel, Zero Gravity Corporation gets you there 15 times, for 20 to 30 seconds each, in a trip, through aerobatic manoeuvres.
Virgin Galactic is reportedly charging up to $250,000 (NZ$375,000) for its trips. Reuters reported that Blue Origin will charge between $200,000 (NZ$299,000) and $300,000 (NZ$349,000).
For the biggest spenders, Bigelow Space Operations has set the price of a space station trip at $52 (NZ$78) million; most of that cost is to get there. NASA estimated that staying at the station would set travelers back about $35,000 (NZ$52,000) a night.
Space Adventures does not list prices on its website. (If you have to ask, you probably can't afford it.) The last tourist in space, Cirque du Soleil founder Guy Laliberté, reportedly paid $35 (NZ$52) million for his 2009 trip to the space station arranged by the company in partnership with Russia's space agency.
How Jeff Bezos helped NBA legend 'quadruple' his fortune
Comedown: Cirque du Soleil founder Guy Laliberté, reportedly paid $35 million to get to space. Photo / Getty Images
The option of least resistance is Zero Gravity Corporation, which sells a single seat on its flights (which, again, don't actually go to space) for $5,400 (NZ$8,000) plus tax.
Who can go?
Other than prohibitions associated with cost, no companies have announced any limitations on who can travel. On its website, Virgin Galactic says its plan is to "open space to everybody," from ages "spanning the teens to the 90s."
How soon can people go?
This has been a moving target for more than a decade, and initial dates are still not firm. Virgin Galactic's chairman said Tuesday that it expected to fly its first customers within a year, but with a backlog of hundreds, the wait would still be extensive. Blue Origin has not yet opened reservations or even flown a test flight with humans. And SpaceX has said its trip around the moon could not happen before 2023.
What kind of training is necessary?
Astronauts who fly with space programs are subject to high fitness standards and rigorous training. Space tourists, not so much.
Blue Origin says passengers will learn everything they need to know the day before launch, including "mission and vehicle overviews, in-depth safety briefings, mission simulation and instruction on your in-flight activities such as operational procedures, communications and maneuvering in a weightless environment."
Space Odyssey: We think we know what space tourism might look like, but how much will it cost? Photo / George Rinhart, Getty Images
Virgin Galactic says training and preparation would take three days: "Pre-flight training will ensure that each astronaut is mentally and physically prepared to savour every second of the spaceflight and fully equipped to fulfill any personal objectives. Our aerospace medical experts will be constantly on hand to offer advice and help, and to check pre-flight fitness," the company says.
Where do I sign up?
For the most part, companies that are moving closer to spaceflight are taking names on their websites. There are also a handful of travel agents accredited for space trips with Virgin Galactic. Bigelow Space Operations essentially tells people to stay tuned: "As you might imagine, as they say 'the devil is in the details,' and there are many."
KLM apologises after revealing where in a plane you are most likely to die
Hidden danger in your duty-free shopping receipt
Comment: It's a popular fad that has screamed 'bad idea' and the ABs aren't buying it.
Calum Henderson reviews Shortland Street's winter season premiere


This topic provides an overview of the properties that make up CSS3 Transitions, and shows you a simple example of transitions in use.
For a list of CSS properties that you can apply transitions to, see Animation and transition properties.
You use the transition-property property to identify one or more CSS properties to which the transition effect(s) will be applied when a new property value is specified.
none No transition effect is applied when a new property value is specified. All transition properties are ignored.
all This is the default value. Every property that supports transitions has the transition effect applied when a new value for the property is specified.
In addition to applying transitions to the more basic CSS properties such as positioning, color, fonts, and so on, you can also apply transitions to newly-supported CSS properties such as opacity and border-radius, and to 2-D and 3-D transforms.
Be aware that, when you interrupt a transition, it reverses automatically.
Specifies one or more comma-separated time values, each of which indicates the length of time that a transition from the old value to the new value takes. Each value is in the form of a floating-point number, followed by a time unit designator (ms or s).
The transition-timing-function property enables a transition to change speed over its duration by describing how the intermediate values used during a transition will be calculated. You do this by specifying an animation timing function that is based on a cubic Bézier curve, which takes four parameters.
You can either specify the curve explicitly by using the cubic-bezier function and entering the four values manually, or you can choose from several function keywords, each of which corresponds to a commonly used timing function.
Specifies one or more comma-separated timing functions that define the intermediate property values used during a transition on a set of corresponding object properties. The possible values can be any of the following. See the transition-timing-function reference page for descriptions of each function.
cubic-bezier(x₁,y₁,x₂,y₂) The four parameters of this function must be floating point values between 0 and 1, inclusive. The values correspond to the x- and y-coordinates of the P₁ and P₂ points of the cubic Bézier curve. For properties other than opacity and color, the cubic-bezier curve function accepts y-coordinates outside the standard range of between 0 and 1. This enables you to create "elastic" or "bounce" transition effects.
ease This is the default value. This timing function gradually increases in speed at the start, animates at full speed, and then gradually decreases in speed at the end.
linear This timing function has a consistent speed from start to end.
ease-in This timing function gradually increases in speed at the start.
ease-out This timing function gradually decreases in speed at the end.
ease-in-out This timing function gradually increases in speed at the start and then gradually decreases in speed at the end.
steps This timing function defines a stepped timing function, and takes two parameters. The first parameter specifies the number of intervals; the optional second parameter specifies the point in the interval where the property value changes. The second parameter is constrained to the values start or end, which is the default.
The transition-delay property enables you to delay the start of a transition, or make it appear as if the transition is already in progress. If the value for the transition-delay property is a negative value, the transition will execute as soon as it is applied, but will appear to have begun execution at the specified offset, or during its play cycle.
Specifies one or more comma-separated offset values within a transition (the amount of time from the start of a transition) before the transition is displayed for a set of corresponding object properties. Each value is in the form of a floating-point number, followed by a time unit designator (ms or s).
The transition shorthand property combines the four transition properties described previously into a single property.
If you have more than one set of the four transition property values, you must separate each set using a comma.
You can see CSS3 transitions in action by going to Hands On: transitions on the IE Test Drive.
The following simple example shows how to use CSS3 transitions to vary one CSS property applied to a div element over time.
Duis ac leo sit amet lectus tristique pulvinar nec rutrum dolor.
Now, when you click and hold (or press and hold) the green div, it will disappear immediately, for as long as the mouse is clicked (or your finger is held down). View this page.
This property adds a color transition to purple over two seconds using the ease timing function. There is no delay value, so the transition begins immediately. View this page.
The transitionstart event occurs at the beginning of the transition.
The transitionend event occurs at the completion of the transition. If the transition is removed before completion, the event will not fire.
This example applies transitions to a <div> element, and fires the transitionstart and transitionend events to change the text in the box. Try the example online.


This peachy cake is lovely and light and makes a delicious pudding served with whipped cream, ice cream or Greek yoghurt.
If using tinned peaches, make sure you drain the peaches well, before use.
Drain the peaches while making the cake batter.
Preheat oven to 180deg C (350deg F). Grease a 22cm cake tin.
Beat butter and sugar with an electric beater until light and fluffy. Add egg and beat well.
Add half the flour and half the milk, and combine. Add remaining flour and milk and mix together.
Pour batter into prepared cake tin. Place peach slices on top and push lightly into the batter. Bake in oven for 1 hour or until cake is cooked through.
Sprinkle with icing sugar and cinnamon while still warm. Serve warm.


Defying Procrastination: What Mother Would Say?
"Has it really been twenty-five years? I've watched you grow from the heavens. Oh, how I've enjoyed it. You make my heart smile. I cry for you too. I know you want to be with me, but not now, son. Not now."
"Like" Defying Procrastination on Facebook!
I loved the voice you created and the idea of her watching over him in heaven. It caught my heart. My mom died when I was 24. Not a day goes by that I don't think of her and wonder if she can see how I am doing. This is great...really tugs the ole heartstrings.
What a sweet thing to daydream about, no? Nice response.
Thank you everyone, I really appreciate the feedback. Today my mother would have turned 80 years old. R.I.P.
Available on Amazon - 100% of the proceeds benefit the fight against Breast Cancer.
Subscribe to get my writing delivered straight to your virtual mailbox.
Grab this Badge if you would like to kick Procrastination in the teeth!
Michael A. Walker. Powered by Blogger.


text:
Jazzalogue No 1
Joseph Turrin
Year:1997 / 2002
Difficulty: VI (see Ratings for explanation)
Publisher: C Alan / McClaren Productions
Cost: Score and Parts (print) - $50.00
Horn in F I-II-III-IV
This kickin' piece for brass ensemble is in a Latin jazz style and is perfect as an opener or an encore. The New York Philharmonic commissioned Turrin to write Jazzalogue No. 1 for the brass section on their 1997 Latin American Tour.
Jazzalogue No. 1 was commissioned and performed by the New York Philharmonic (as an encore piece) for their 1997 Latin American Tour. The first performance took place just before the tour, at the last concert of the season on May 31, 1997, at Avery Fisher Hall. The work was not on the program, but Kurt Masur (from on stage) introduced it to the audience as a surprise. In the following year, the orchestra used Jazzalogue No. 1 on their 1998 tour of Asia.
- Program Note from Baylor University Wind Ensemble concert program, 23 October 2018
Audio CD: Pacific Symphonic Wind Ensemble (Vancouver, B.C.) (Marc Compton, conductor) - 2005
Audio: recording. Ensemble and conductor unknown
Audio: Baylor University Wind Ensemble Brass
Baylor University (Waco, Texas) Wind Ensemble (Eric Wilson, conductor) – 23 October 2018
State University of New York, Potsdam, Crane Wind Ensemble (Brian K. Doyle, conductor) – 19 April 2017
novaBRASS (Slovenia) – 25 December 2015
Arabesque (1990/2004)
Celebration (2010)
Chronicles (2000)
Concert Processional (2011)
Concertino for 11 Instruments and Wind Ensemble (2011)
Dedication for Band (2009)
Fandango: For Solo Trumpet, Trombone and Wind Symphony (1999)
Fanfare and Prelude (2009)
Hemispheres (2002)
High Flight (2008)
Hope Alive
Illuminations (2004)
Invocation (1992)
Jazzalogue No 1 (1997/2002)
Lullaby for Noah (2008)
Nessum Dorma (as arranger)
Quadrille (2002)
Regiment of Heroes March (2016)
Ritual. See: Soundings for Band (1997)
Scarecrow Overture (2009)
Serenade Romantic (1982)
The Sounding of the Call (2014)
Soundings for Band (1997)
Ritual (2011)
Two Sketches for Band
Zarabanda
Turrin, J. (2002). Jazzalogue No. 1: Brass Ensemble [score]. C. Alan Publications: Greensboro, N.C.
Retrieved from "https://www.windrep.org/index.php?title=Jazzalogue_No_1&oldid=111229"


text:
PTC Therapeutics Reports Third Quarter 2019 Financial Res...
PTC Therapeutics Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
SOUTH PLAINFIELD, N.J., Oct. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2019.
"We are following through on our commitment to build an innovative, diversified rare disorders company," said Stuart Peltz, Ph.D., CEO of PTC Therapeutics. "This quarter, we completed a successful financing to continue to drive our internal programs while continuing to evaluate select external opportunities. This most recent financing has put us in a position to execute on our strategic vision of reaching over $1.5B in revenue by 2023."
Corporate Highlights:
Tegsedi® (inotersen) received approval from the Brazilian health regulatory authority (ANVISA) for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR), to delay disease progression and improve quality of life. This approval will allow PTC to initiate the launch in Brazil with the only hATTR indication globally to include improvements in quality of life.
PTC acquired assets from BioElectron Technology Corporation that are focused on inflammatory and central nervous system (CNS) disorders. The lead program is pivotal trial ready for CNS disorders with substantial unmet need and significant commercial opportunity that are complementary to PTC's existing pipeline.
Advancing CNS Gene Therapy Portfolio & Infrastructure:
PTC has entered into a strategic collaboration with Aldevron to support GMP plasmid manufacturing for the gene therapy portfolio.
As previously disclosed, PTC is on track to submit a BLA with the FDA in late 2019 followed by an MAA in Europe for the AADC deficiency gene therapy program. This will be followed by an anticipated commercial launch in 2020.
Data presented in October at the Child Neurology Society meeting demonstrated that patients receiving PTC-AADC had sustained motor, cognitive, and language milestones representing up to five years of follow up post-treatment.
The Friedreich ataxia program continues to advance with an IND submission now expected in mid-2020.
PTC has signed a long-term lease agreement securing a state-of-the-art biologics facility located in Hopewell, N.J. to support the research and operations of multiple gene therapy programs.
Updates for Small Molecule Splicing Platform:
Data from pivotal FIREFISH and SUNFISH part 1 studies were presented at the World Muscle Society Congress in October, demonstrating continued clinical benefit with risdiplam in Type 1, 2, and 3 SMA patients.
In part 1 of FIREFISH, babies with Type 1 SMA continue to achieve motor milestones including at least one patient now standing and two patients starting to walk.
Risdiplam continues to be well tolerated at all doses across studies and there have been no drug related safety findings leading to withdrawal.
Part 2 SUNFISH data is expected by the end of the year followed by part 2 FIREFISH data in early 2020.
Planned NDA filing with the FDA is on track for the second half of this year with the intention to support a broad label to treat SMA Types 1, 2, & 3 patients. Filing of the MAA in the EU is expected to occur in the first half of 2020.
Based on initial feedback from the FDA on the complexity of a clinical pathway for the small population of patients, PTC has decided to discontinue the Familial Dysautonomia oral splicing program.
PTC continues to prioritize our Huntington's program, which is scaling up with safety and toxicology work and is expected to enter the clinic in 2020.
PTC Full Year 2019 Guidance:
PTC anticipates DMD franchise net product revenues for the full year 2019 to remain between $285 and $305 million.
PTC anticipates GAAP R&D and SG&A expense for the full year 2019 to be between $420 and $430 million.
PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2019 to be between $380 and $390 million, an increase from $360 and $370 million, excluding estimated non-cash, stock-based compensation expense of approximately $40 million, an increase from $35 million. This increase in operating expense is primarily due to the acceleration of activities in our core programs, including research and gene therapy manufacturing.
Third Quarter 2019 Financial Highlights:
Total revenues were $71.4 million for the third quarter of 2019, compared to $53.6 million for the third quarter of 2018.
Translarna™ net product revenues were $48.3 million for the third quarter of 2019, compared to $30.4 million for the third quarter of 2018. These results reflect the expanded commercialization of Translarna.
Emflaza® net product revenues were $22.9 million for the third quarter of 2019, compared to $22.6 million for the third quarter of 2018. These results reflect an increase in the utilization of Medicaid which changed our gross to net assumptions and includes the impact of transitioning to a new specialty pharmacy distributor.
GAAP R&D expenses were $63.1 million for the third quarter of 2019, compared to $54.4 million for the third quarter of 2018. The increase in R&D expenses reflects costs associated with advancing the gene therapy platform and increased investment in research programs as well as advancement of the clinical pipeline.
Non-GAAP R&D expenses were $58.1 million for the third quarter of 2019, excluding $5.0 million in non-cash, stock-based compensation expense, compared to $49.9 million for the third quarter of 2018, excluding $4.4 million in non-cash, stock-based compensation expense.
GAAP SG&A expenses were $49.3 million for the third quarter of 2019, compared to $38.4 million for the third quarter of 2018. The increase in SG&A expenses was primarily due to continued investment in support of our commercial activities.
Non-GAAP SG&A expenses were $43.8 million for the third quarter of 2019, excluding $5.5 million in non-cash, stock-based compensation expense, compared to $33.9 million for the third quarter of 2018, excluding $4.5 million in non-cash, stock-based compensation expense.
Change in the fair value of deferred and contingent consideration was $9.5 million for the third quarter of 2019. The change in fair value of deferred and contingent consideration is related to the fair valuation of potential future consideration to be paid to former equity holders of Agilis Biotherapeutics, Inc. (Agilis) in connection with PTC's acquisition of Agilis, which closed in August 2018.
Net loss was $60.0 million for the third quarter of 2019, compared to net loss of $51.0 million for the third quarter of 2018.
Cash, cash equivalents, and marketable securities were $708.6 million at September 30, 2019, compared to $227.6 million at December 31, 2018. We completed a financing that amounted to $287.5 million in convertible bonds and $100.0 million in equity for a total consideration of $387.5 million, resulting in net offering proceeds of $376.3 million.
Shares issued and outstanding as of September 30, 2019 were 61,578,992.
Upcoming investor conferences
Credit Suisse 28th Annual Healthcare Conference, November 12th 2:25 pm MT.
Non-GAAP Financial Measures:
In this press release, the financial results and financial guidance of PTC are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.
Today's Conference Call and Webcast Reminder:
Today's conference call will take place at 4:30 pm ET and can be access by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 9224968. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor relations section of the PTC website. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for two weeks.
About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us on www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
akane@ptcbio.com
Jane Baj
jbaj@ptcbio.com
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "PTC Full Year 2019 Guidance", including with respect to (i) 2019 net product revenue guidance and (ii) 2019 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions; PTC's expectations with respect to the licensing, regulatory submissions and potential commercialization of Tegsedi and Waylivra; expansion of commercialization of Translarna and Emflaza and related regulatory submissions; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions or royalty or milestone payments; PTC's strategy, future operations, future financial position, future revenues, projected costs; the intended use of proceeds from PTC's public offering of common stock and private offering of convertible senior notes; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for Emflaza and Translarna and any other product candidates that PTC may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before approving Emflaza prescription reimbursement; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the potential financial impact or PTC's ability to realize the anticipated benefits of the acquisition of Agilis and its gene therapy platform, including with respect to the business of Agilis and expectations with respect to the potential achievement of development, regulatory and sales milestones and contingent payments to the former Agilis equity holders with respect thereto and PTC's ability to obtain marketing approval of PTC-AADC and other product candidates acquired from Agilis, will not be realized or will not be realized within the expected time period; expectations with respect to the potential financial impact and benefits of the collaboration and licensing agreement with Akcea Therapeutics, Inc., including with respect to the timing of regulatory approval of Tegsedi and Waylivra in countries in Latin America and the Caribbean, the commercialization of Tegsedi and Waylivra, and PTC's expectations with respect to contingent payments to Akcea based on net sales and the potential achievement of regulatory milestones; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions with regards to risdiplam; significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition of its gene therapy pipeline, as well as other business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra, risdiplam or any of PTC's other product candidates; PTC's scientific approach and general development progress; expectations with respect to the potential financial impact and benefits of its leased biologics facility and PTC's ability to satisfy its obligations under the terms of the lease agreement for such facility; PTC's ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or risdiplam.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
PTC Therapeutics, Inc.
Consolidated Statements of Operations
Net product revenue
Collaboration and grant revenue
Cost of product sales
Amortization of Acquired intangible asset
Selling, general and administrative (2)
Change in the fair value of deferred and contingent consideration
Loss from operations
Interest expense, net
Other (expense) income, net
Loss before income tax expense
Net loss attributable to common stockholders
Weighted-average shares outstanding:
Basic and diluted (in shares)
Net loss per share—basic and diluted (in dollars per share)
(1) Research and development reconciliation
GAAP research and development
Less: share-based compensation expense
Non-GAAP research and development
(2) Selling, general and administrative reconciliation
GAAP selling, general and administrative
Non-GAAP selling, general and administrative
Summary Consolidated Balance Sheets
(in thousands, except share data)
Cash, cash equivalents and marketable securities
Total deferred revenue
Total stockholders' equity (61,578,992 and 50,606,147 common shares issued and outstanding at September 30, 2019 and December 31, 2018 respectively)
Reconciliation of GAAP to Non-GAAP Projected Full Year 2019 R&D and SG&A Expense
Low End of Range
High End of Range
Projected GAAP R&D and SG&A Expense
Less: projected non-cash, stock-based compensation expense
Projected non-GAAP R&D and SG&A expense
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-reports-third-quarter-2019-financial-results-and-provides-a-corporate-update-300947573.html
SOURCE PTC Therapeutics, Inc.


Journeys, expectations, dreams and reality weave alongside the ordinary every day in Novi Sad. Captured in 35mm, Nebo, meaning 'sky' underscores the bold colours and textures of life in the artist's Serbian motherland.
Loren Lazić-Duffy is a British-born Serb who undertook a courageous journey to discover her Motherland through her passion – photography.


text:
Janice Demers
Share Janice's life story with friends and family
Janice P. (Patrie) Demers, 93, passed away peacefully at home on January 11, 2021 with family by her side. She was born in Chicopee in 1927 to Armand and Charlotte (Hickory) Patrie, attending St. Joan of Arc Elementary School and Cathedral High School Class of 1945. She was predeceased by her "perfect" husband of 55 years, Albert Paul Demers, in 2007. Janice's memory lives on in her children, James (former wife Mary Morry) of Brooklyn, NY, Christopher (wife Kathy) of Willington, CT and Charlotte (partner Paige Garvey) of Newcomb, NY. She was predeceased by her son, Kenneth, in 2017 (wife Noreen) of Adams, MA. She also leaves behind her three grandchildren, Ryan Demers (wife Tara Glynn) of Plattsburgh, NY, Daniel Demers (wife Brooke Sheeran) of Newmarket, NH and Alexandra Demers of Madison, WI; and her great grandson, Teague Demers with another two great grandchildren on the way. Janice also leaves two brothers, James and David Patrie (wife Betty), and was predeceased by three brothers, Thomas, Gerald and Robert Patrie; two sisters, Jackie Willemain and Carol Rogalski; as well as two sisters-in-law, Mary Patrie and Dorie Patrie. Janice enjoyed summers with Albert at the Whitecaps Campground on Lake Willoughby, VT as well as skiing, golfing and road trips with her friends and hosting holidays with her family. She especially enjoyed cuddling babies as a volunteer in the Neonatal Intensive Care Unit at Baystate Medical Center. The family wishes to offer heartfelt thanks to longtime neighbors, Sue Lemieux, Jeannette and Jim Montemagni and Gary and Donna Labrie for their support through the years, as well as Samantha Farquhar for her kind and gentle home care help. A graveside service at Sainte Rose Cemetery will be announced at a later date. There are no visiting hours at the St. Pierre – Phaneuf Aldenville Chapels, (413-532-9806), 13 Dale Street, Chicopee, MA 01020. Donations may be made in her memory to Lorraine's Soup Kitchen and Pantry, 170 Pendexter Avenue, Chicopee, MA 01013 or Trinity Health of New England at Home, 200 Hillside Circle, Suite 3, West Springfield, MA 01089 or Saint Joan of Arc School, 587 Grattan Street, Chicopee, MA 01020. For more details and to leave her family online condolences, please visit: www.stpierrephaneuf.com
Published in The Republican from Jan. 13 to Jan. 14, 2021.
St Pierre Phaneuf Aldenville Funeral Chapel
13 Dale St
Peace be with you Aunt Janice,I will always remember your wonderful backyard picnics,your lovely smile, and our happy times joy and togetherness.My prayers ,my love, Aunt Janice
Diana Marie Rogalski
Janice was a joy to have at our community Hillside residence we will miss her
Deborah Duncan
Charlotte and Family,
My deepest condolences on the loss of your Mother. So sorry I never had the pleasure of meeting her. Jim said she was a very happy, nice lady and that all of you had many good times together. You are all in my thoughts and prayers at this most difficult time. May fond memories comfort you always.
Rita Gaudet
Janice was a sweet lady who helped me sew a pair of pants for the first time. Patient, encouraging and funny. Long time since our last meeting but i will never forget her. My condolences to all her family, especially Jamie, Chris and Charlotte, my childhood friends.
Leslie Niquette
Janice was a very talented mother and wife. She was the person who taught me how to sew my many pieces of clothing. Living next door she was my go to Aunt as a youngster. Very happy times. She will be joining her loved ones for a well deserved reunion in heaven.
Jackie Lavoie